In Novo pricing probe, Sanders cranks up the heat with dire warning on projected GLP-1 spending

After recently placing a spotlight on Novo Nordisk’s "outrageous" U.S. pricing for GLP-1 drugs, Sen. Bernie Sanders is doubling down on his cost fighting crusade. This time, the senator is flagging budgetary concerns related to the GLP-1 class of diabetes and obesity medicines.